 |
3 Products |  |
4 Diseases | | 3 Products |
|
4 Trials |  |
130 News |  |
| 12» |
- prexigebersen (BP1001) - Bio / Path
INTERIM SAFETY AND EFFICACY OF BP1001 IN A PHASE II ACUTE MYELOID LEUKEMIA STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1347;
P2a
Since >5 responses are observed in both cohorts, the study will continue with enrollment up to 98 and 54 evaluable patients in cohorts 1 and 2, respectively. Efficacy data are encouraging in a challenging population of frontlineadverse-risk, sAML and R/R patients.
- prexigebersen (BP1001) - Bio / Path
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study. (E450b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1148;
P2a
Since >5 responses are observed in both cohorts, the study will continue with enrollment up to 98 and 54 evaluable pts in cohorts 1 and 2, respectively. Efficacy data are encouraging in a challenging population of frontline adverse-risk, sAML and R/R pts.
- | BP1002 - Bio / Path
Trial completion date, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Feb 21, 2024
P1, N=30, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Efficacy data are encouraging in a challenging population of frontline adverse-risk, sAML and R/R pts. Trial completion date: Jan 2025 --> Jan 2026
- | BP1002 - Bio / Path
Trial completion date, Trial primary completion date, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Oct 12, 2023
P1, N=30, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Jan 2025 --> Jan 2026 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
- || prexigebersen (BP1001) - Bio / Path
Trial completion date, Trial primary completion date, Combination therapy: BP1001-201-AML: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - Feb 10, 2023
P2a, N=108, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- || BP1002 - Bio / Path
Enrollment open: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 22, 2022
P1, N=48, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Not yet recruiting --> Recruiting
- || prexigebersen-A (BP1001-A) - Bio / Path
Enrollment open, Trial completion date, Trial primary completion date, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 23, 2022
P1, N=50, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- || BP1002 - Bio / Path
Trial initiation date: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jun 8, 2022
P1, N=48, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Initiation date: Apr 2022 --> Jul 2022
- | BP1002 - Bio / Path
Trial completion date, Trial primary completion date, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Mar 10, 2022
P1, N=30, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Initiation date: Apr 2022 --> Jul 2022 Trial completion date: Aug 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Sep 2023
- || BP1002 - Bio / Path
Trial initiation date: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Mar 9, 2022
P1, N=48, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Aug 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Sep 2023 Initiation date: Jan 2022 --> Apr 2022
- 5-fluorouracil / Generic mfg., paclitaxel / Generic mfg.
Targeting STAT3 with novel liposome-incorporated antisense oligonucleotide technology enhances the efficacy of paclitaxel (taxol) and 5-fluorouracil (5-FU) in breast and ovarian cancer cells (Section 24) - Mar 9, 2022 - Abstract #AACR2022AACR_5403;
These results are in line with previous work in which BP1003 + gemcitabine displayed enhanced anti-tumor activity in pancreatic ductal adenocarcinoma. Together these results strongly suggest that BP1003 combination therapy is a novel strategy for patients with advanced solid tumors.
- || BP1002 - Bio / Path
New P1 trial: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jan 12, 2022
P1, N=48, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
- || prexigebersen (BP1001) - Bio / Path
Trial completion date, Trial primary completion date, Combination therapy: BP1001-201-AML: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - Jan 4, 2022
P2a, N=108, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Together these results strongly suggest that BP1003 combination therapy is a novel strategy for patients with advanced solid tumors. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | prexigebersen-A (BP1001-A) - Bio / Path
Trial completion date, Trial primary completion date, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Dec 22, 2021
P1, N=50, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
- prexigebersen (BP1001) - Bio / Path
Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML) (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2844;
P2a
Preliminary data showed the combination treatment of BP1001 + DAC or BP1001 + DAC + VEN was well-tolerated, with encouraging efficacy signals. The study will continue enrollment across all three cohorts.
- | BP1003 - Bio / path
$BPTH Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 https://t.co/EALmBZ5bp9 #patent (Twitter) - Jun 22, 2021
- || prexigebersen (BP1001) - Bio / Path
Review, Journal: The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. (Pubmed Central) - May 1, 2021
Focusing on liposomal delivery, we will specifically describe liposome-incorporated growth factor receptor-bound protein-2 (Grb2) antisense oligodeoxynucleotide BP1001...Additionally, its enhanced biodistribution makes it an attractive therapeutic modality for hematologic malignancies as well as solid tumors. A detailed understanding of the obstacles that ASOs face prior to reaching their targets and continued advances in methods to overcome them will allow us to harness ASOs' full potential in precision medicine.
- Venclexta (venetoclax) / Roche, AbbVie, liposomal Bcl2 (BP1002) - Bio / Path
[VIRTUAL] The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells () - Mar 11, 2021 - Abstract #AACR2021AACR_2035;
Our data indicate that, despite expressing higher levels of anti-apoptotic proteins, venetoclax-resistant cells are sensitive to the BP1002 plus decitabine combination. These promising preclinical results suggest that the BP1002 plus decitabine combination is a potential treatment for patients who have relapsed from frontline venetoclax-based therapies.
- | BP1002 - Bio / Path
Trial completion date, Trial primary completion date, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Jan 27, 2021
P1, N=30, Recruiting, Sponsor: Bio-Path Holdings, Inc.
These promising preclinical results suggest that the BP1002 plus decitabine combination is a potential treatment for patients who have relapsed from frontline venetoclax-based therapies. Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
- | prexigebersen-A (BP1001-A) - Bio / Path
Trial completion date, Trial primary completion date, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Jan 26, 2021
P1, N=50, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Feb 2021 --> Feb 2022 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- || BP1002 - Bio / Path
Enrollment open, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Sep 13, 2020
P1, N=30, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Not yet recruiting --> Recruiting
- || prexigebersen-A (BP1001-A) - Bio / Path
Trial initiation date, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 27, 2020
P1, N=50, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Not yet recruiting --> Recruiting Initiation date: Jul 2020 --> Oct 2020
- BP1003 - Bio / path, liposomal Bcl2 (BP1002) - Bio / path, prexigebersen (BP1001) - Bio / path
[VIRTUAL] Bio-Path Holdings Inc. () - Jun 9, 2020 - Abstract #BIO2020BIO_130;
Bio-Path is initiating a Phase 1 study of its 2nd pipeline candidate, BP1002 (liposomal Bcl-2), in the 1st half of 2020 to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. And BioPath is nearing completion of IND-enabling studies of BP1003, a novel liposome- incorporated STAT3.
- | prexigebersen (BP1001) - Bio / Path
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy: Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (clinicaltrials.gov) - May 28, 2020
P1/2, N=0, Withdrawn, Sponsor: Bio-Path Holdings, Inc.
And BioPath is nearing completion of IND-enabling studies of BP1003, a novel liposome- incorporated STAT3. N=46 --> 0 | Trial completion date: Dec 2021 --> May 2020 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> May 2020
- || BP1002 - Bio / Path
Trial initiation date, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - May 27, 2020
P1, N=30, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
N=46 --> 0 | Trial completion date: Dec 2021 --> May 2020 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> May 2020 Initiation date: Feb 2020 --> Jun 2020
- ||| prexigebersen (BP1001) - Bio / Path
Trial completion: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - May 27, 2020
P1, N=60, Completed, Sponsor: Bio-Path Holdings, Inc.
Initiation date: Feb 2020 --> Jun 2020 Active, not recruiting --> Completed
- || prexigebersen-A (BP1001-A) - Bio / Path
Trial initiation date, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - May 27, 2020
P1, N=50, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
Active, not recruiting --> Completed Initiation date: Feb 2020 --> Jul 2020
- prexigebersen (BP1001) - Bio / path, decitabine / Generic mfg.
[VIRTUAL] A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies. (Poster Board 334) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2102;
P2a
The exploratory objective of this study is to evaluate the association of treatment response with cytogenetic and molecular characteristics. Research Funding: Bio-Path Holdings, Inc.
- liposomal Bcl2 (BP1002) - Bio / path
[VIRTUAL] A phase I clinical trial to study the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_421;
The dose below that will be the maximum tolerated dose (MTD). The RP2D will be determined using the MTD data and all information regarding safety, biological activity, PK and pharmacodynamics.Primary objectives: To determine•Safety and tolerability of escalating doses of BP1002•RP2D of BP1002•PK of BP1002•BP1002 activity on Bcl-2 expressionSecondary objectives: To obtain evidence of tumor response (overall response rate = complete remission + partial remission + minor response), and estimates for other response parameters (time to progression, progression-free survival, event-free survival)Exploratory objectives: To correlate treatment response with biological activity, cytogenetic and molecular characteristicsSafety assessments will include identification of DLTs, serious adverse events, treatment-emergent adverse events and treatment-emergent laboratory abnormalitiesResponse assessments will be determined per the 2018 International Workshop Group on CLL (iwCLL) response criteria, the International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017), or the Eighth International Workshop for Waldenströms Macroglobulinemia response criteria.
- Avastin (bevacizumab) / Roche, paclitaxel / Generic mfg.
A needle in a haystack: Targeting growth factor receptor bound protein-2 (Grb2) as a novel therapeutic in uterine carcinoma (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_2589;
Grb2 amplification was related to decreased patient survival (P < 0.001), suggesting it may be an attractive therapeutic target. Grb2 was expressed in most uterine cancer cell lines (KLE, Hec1a, Ishikawa, and MFE319).
- Avastin (bevacizumab) / Roche, paclitaxel / Generic mfg.
A needle in a haystack: Targeting growth factor receptor bound protein-2 (Grb2) as a novel therapeutic in uterine carcinoma (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1957;
Grb2 amplification was related to decreased patient survival (P < 0.001), suggesting it may be an attractive therapeutic target. Grb2 was expressed in most uterine cancer cell lines (KLE, Hec1a, Ishikawa, and MFE319).
- Avastin (bevacizumab) / Roche, paclitaxel / Generic mfg.
A needle in a haystack: Targeting growth factor receptor bound protein-2 (Grb2) as a novel therapeutic in uterine carcinoma (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1300;
Grb2 amplification was related to decreased patient survival (P < 0.001), suggesting it may be an attractive therapeutic target. Grb2 was expressed in most uterine cancer cell lines (KLE, Hec1a, Ishikawa, and MFE319).
- Avastin (bevacizumab) / Roche, paclitaxel / Generic mfg.
A needle in a haystack: Targeting growth factor receptor bound protein-2 (Grb2) as a novel therapeutic in uterine carcinoma (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_665;
Grb2 amplification was related to decreased patient survival (P < 0.001), suggesting it may be an attractive therapeutic target. Grb2 was expressed in most uterine cancer cell lines (KLE, Hec1a, Ishikawa, and MFE319).
- || prexigebersen-A (BP1001-A) - Bio / Path
New P1 trial, Metastases: BP1001-A in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Dec 12, 2019
P1, N=50, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
- || liposomal Bcl2 (BP-100-1.02) - Bio / path
IND: #BioPathHoldings Announces Clearance Of #InvestigationalNewDrug Application For #BP1002 $BPTH https://t.co/dYUBOQ08Rb (Twitter) - Nov 22, 2019
- | BP1002 - Bio / Path
New P1 trial, IO biomarker, Metastases: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov) - Aug 28, 2019
P1, N=30, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
- || prexigebersen (BP1001) - Bio / Path
Trial completion date, Trial primary completion date, Combination therapy: BP1001-201-AML: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - Jun 13, 2019
P2a, N=108, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Grb2 was expressed in most uterine cancer cell lines (KLE, Hec1a, Ishikawa, and MFE319). Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
- ||| prexigebersen (BP1001) - Bio / Path
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: BP1001-201-AML: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - Jan 25, 2019
P2a, N=108, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021 N=54 --> 108 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | prexigebersen (BP1001) - Bio / Path
Trial completion date, Trial primary completion date, Combination therapy: Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (clinicaltrials.gov) - Jan 25, 2019
P1/2, N=46, Recruiting, Sponsor: Bio-Path Holdings, Inc.
N=54 --> 108 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Nov 2020 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Dec 2020
- | prexigebersen (BP1001) - Bio / Path
Clinical, P1 data, Journal: Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. (Pubmed Central) - Sep 6, 2018
P1
BP1001 is well tolerated, with early evidence of anti-leukaemic activity in combination with low-dose cytarabine. To further explore this anti-leukaemic activity, the efficacy of BP1001 plus low-dose cytarabine combination is being investigated in an ongoing phase 2 study in patients with previously untreated acute myeloid leukaemia who are ineligible for intensive induction therapy.
- || prexigebersen (BP1001) - Bio / Path
Trial primary completion date: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - Jan 18, 2018
P1, N=60, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
To further explore this anti-leukaemic activity, the efficacy of BP1001 plus low-dose cytarabine combination is being investigated in an ongoing phase 2 study in patients with previously untreated acute myeloid leukaemia who are ineligible for intensive induction therapy. Trial primary completion date: Sep 2017 --> Dec 2019
- | prexigebersen (BP1001) - Bio / Path
Enrollment open, Trial initiation date, Combination therapy: Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (clinicaltrials.gov) - Jan 18, 2018
P1/2, N=46, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial primary completion date: Sep 2017 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Sep 2017
- || prexigebersen (BP1001) - Bio / Path
Trial primary completion date: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - Jul 26, 2017
P1, N=60, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Sep 2017 Trial primary completion date: May 2017 --> Sep 2017
- || prexigebersen (BP1001) - Bio / Path
Trial primary completion date: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - Feb 1, 2017
P1, N=60, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- | prexigebersen (BP1001) - Bio / Path
New P1/2 trial, Combination therapy: Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (clinicaltrials.gov) - Oct 5, 2016
P1/2, N=46, Not yet recruiting, Sponsor: Bio-Path Holdings, Inc.
- |||| prexigebersen (BP1001) - Bio / Path
Enrollment open, Combination therapy: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - Aug 8, 2016
P2a, N=54, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial primary completion date: Sep 2016 --> Mar 2017 Active, not recruiting --> Recruiting
- || prexigebersen (BP1001) - Bio / Path
Trial primary completion date: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - Jul 20, 2016
P1, N=60, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Sep 2016
- ||||| prexigebersen (BP1001) - Bio / Path
New P2a trial, Combination therapy: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (clinicaltrials.gov) - May 25, 2016
P2a, N=54, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
- || prexigebersen (BP1001) - Bio / Path
Enrollment closed: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - May 19, 2016
P1, N=60, Active, not recruiting, Sponsor: Bio-Path Holdings, Inc.
Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- || prexigebersen (BP1001) - Bio / Path
Trial primary completion date: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (clinicaltrials.gov) - Jan 17, 2016
P1, N=60, Recruiting, Sponsor: Bio-Path Holdings, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Apr 2016